Pharmacotherapy of type 2 diabetes: An update

被引：153

作者：

Upadhyay, Jagriti ^{[1
,2
]}

Polyzos, Stergios A. ^{[3
]}

Perakakis, Nikolaos ^{[2
,4
,5
]}

Thakkar, Bindiya ^{[1
]}

Paschou, Stavroula A. ^{[2
]}

Katsiki, Niki ^{[6
]}

Underwood, Patricia ^{[1
]}

Park, Kyung-Hee ^{[7
]}

Seufert, Jochen ^{[4
,5
]}

Kang, Eun Seok ^{[8
]}

Sternthal, Elliot ^{[1
]}

Karagiannis, Asterios ^{[3
]}

Mantzoros, Christos S. ^{[1
,2
]}

机构：

[1] Boston VA Healthcare Syst, Sect Endocrinol Diabet & Metab, Boston, MA 02130 USA

[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Dept Internal Med, Boston, MA 02115 USA

[3] Aristotle Univ Thessaloniki, Med Sch, Dept Pharmacol 1, Thessaloniki, Greece

[4] Univ Hosp Freiburg, Div Endocrinol, Dept Internal Med 2, Freiburg, Germany

[5] Univ Hosp Freiburg, Div Diabetol, Dept Internal Med 2, Freiburg, Germany

[6] Aristotle Univ Thessaloniki, Med Sch, Hippocrat Hosp, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[7] Hallym Univ Sacred Heart Hosp, Dept Family Med, Gyeonggi Do, South Korea

[8] Yonsei Univ, Coll Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2018年 / 78卷

关键词：

Algorithm; Goals pharmacotherapy; Personalized therapy; Type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPROVES GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; TWICE-DAILY EXENATIDE; HUMAN GLP-1 ANALOG; BETA-CELL FUNCTION; GLUCOSE COTRANSPORTER-2 INHIBITORS; PREVIOUS MYOCARDIAL-INFARCTION;

D O I：

10.1016/j.metabol.2017.08.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide and a major economic burden. The prevalence of T2DM is rising, suggesting more effective prevention and treatment strategies are necessary. The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM. Each therapeutic class is presented in detail, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations (heart failure, renal insufficiency, obesity and the elderly). We also present representative cost for each antidiabetic category. Then, we provide an individualized guide for initiation and intensification of treatment and discuss the considerations and rationale for an individualized glycemic goal. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：13 / 42

页数：30

共 358 条

[51] Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes [J].

Ceriello, A ;

Eckland, DJ ;

Johns, D ;

Gilmore, KJ ;

Widel, M ;

Tan, MH .

DIABETES CARE, 2005, 28 (02) :266-272

[52] Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update [J].

Ceriello, Antonio ;

Davidson, Jamie ;

Hanefeld, Markolf ;

Leiter, Lawrence ;

Monnier, Louis ;

Owens, David ;

Tajima, Naoko ;

Tuomilehto, Jaakko .

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2006, 16 (07) :453-456

[53] Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [J].

Chacra, A. R. ;

Tan, G. H. ;

Apanovitch, A. ;

Ravichandran, S. ;

List, J. ;

Chen, R. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) :1395-1406

[54] Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes [J].

Chamberlain, James J. ;

Herman, William H. ;

Leal, Sandra ;

Rhinehart, Andrew S. ;

Shubrook, Jay H. ;

Skolnik, Neil ;

Kalyani, Rita Rastogi .

ANNALS OF INTERNAL MEDICINE, 2017, 166 (08) :572-+

[55] Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes [J].

Chapman, I ;

Parker, B ;

Doran, S ;

Feinle-Bisset, C ;

Wishart, J ;

Strobel, S ;

Wang, Y ;

Burns, C ;

Lush, C ;

Weyer, C ;

Horowitz, M .

DIABETOLOGIA, 2005, 48 (05) :838-848

[56] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

[57] A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial [J].

Charbonnel, BH ;

Matthews, DR ;

Schernthaner, G ;

Hanefeld, M ;

Brunetti, P .

DIABETIC MEDICINE, 2005, 22 (04) :399-405

[58] Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus [J].

Cheung, N. Wah ;

Conn, Jennifer J. ;

d'Emden, Michael C. ;

Gunton, Jenny E. ;

Jenkins, Alicia J. ;

Ross, Glynis P. ;

Sinha, Ashim K. ;

Andrikopoulos, Sofianos ;

Colagiuri, Stephen ;

Twigg, Stephen M. .

MEDICAL JOURNAL OF AUSTRALIA, 2009, 191 (06) :339-344

[59] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494

[60] SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria [J].

Chino, Yukihiro ;

Samukawa, Yoshishige ;

Sakai, Soichi ;

Nakai, Yasuhiro ;

Yamaguchi, Jun-ichi ;

Nakanishi, Takeo ;

Tamai, Ikumi .

BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (07) :391-404

← 1 2 3 4 5 6 7 8 9 10 →